Congenital Disorders of Glycosylation: N-Glycan Profile, Qualitative, Plasma

**Test Code:** BNGLY  
**Turnaround time:** 7 days - 10 days  
**CPT Codes:** 82373 x1, 83799 x1, 84375 x1

### Condition Description

Congenital disorders of glycosylation (CDG) comprise a group of multi-system diseases with an extremely variable phenotype. Manifestations range from severe developmental delay and hypotonia with multiple organ system involvement beginning in infancy, to hypoglycemia and protein-losing enteropathy with normal development, or isolated failure to thrive. Type I CDG comprises those disorders in which there are defects that affect the biosynthesis of dolichol-linked oligosaccharides in the cytosol or the endoplasmic reticulum (ER), as well as defects involving the transfer of oligosaccharides onto nascent glycoproteins. Type II CDG comprises all defects of further trimming and elongation of N-linked oligosaccharides in the ER and Golgi.

Serum or plasma N-glycan profile can be used to identify most subtypes of CDG type II, combined type I and type II, and multiple glycosylation disorders, such as various types of COG complex deficiencies (Conserved Oligometric Golgi).

### Educational Materials:
- [CDG Handout for Parents](#)
- [CDG Handout for Clinicians](#)

### References:

### Indications

Manifestations of CDG range from severe developmental delay and hypotonia with multiple organ system involvement to hypoglycemia and protein-losing enteropathy with normal development. The diagnosis should be considered in all patients with failure to thrive, mental retardation, cerebellar hypoplasia, liver dysfunction, or seizures and stroke-like episodes.

### Methodology

N-Glycan chains are firstly released from SDS denaturated serum glycoproteins via PNGase F digestion, and then permethylated. The permethylated N-glycan are measured by matrix-assisted laser desorption/ionization time of light mass spectrometry (MALDI-TOF). The structure of the glycans can be further analyzed by MALDI-TOF/TOF.

### Detection

Comparing to normal serum or plasma, the changes in the N-glycan structure monitored by MALDI profile are used to identify the associated congenital disorders of glycosylation (CDGs) in patients serum or plasma.

### Specimen Requirements

**Additional Specimen Collection/Handling Instructions Required for this Test**  
**Only one specimen type is required for this test: Frozen serum or frozen plasma.**

Submit only 1 of the following specimen types

**Type: Serum**

Specimen Requirements:

In serum (red top) tube:  
Draw 1-5 ml blood  
Centrifuge immediately to separate serum and freeze.

Specimen Collection and Shipping: Ship frozen sample on dry ice with overnight delivery.

**Type: Plasma**

Specimen Requirements:

In sodium heparin (green top) tube:
Draw 1-5 ml blood
Centrifuge immediately to separate plasma and freeze.

Specimen Collection and Shipping: Ship frozen sample on dry ice with overnight delivery.

**Special Instructions**

Click [here](#) for the clinical presentation form.

**Related Tests**

- Carbohydrate Deficient Transferrin for Congenital Disorders of Glycosylation (BCDGS)
- N-glycan and Carbohydrate Deficient Transferrin Panel for CDGs (BCDG)
- Congenital Disorders of Glycosylation: O-glycan Profile and Quantification (BOGLY)
- Oligosaccharide and Glycan Screening (OS)
- Sequencing analysis of individual CDG genes is available.
- Sequencing analysis of different panels for CDG genes are also available.
- Custom diagnostic mutation analysis (KM) is available to family members if mutations are identified by targeted mutation testing or sequencing analysis.
- Prenatal testing is available to adult couples who are confirmed carriers of mutations. Please contact the laboratory genetic counselor to discuss appropriate testing prior to collecting a prenatal specimen.